Btk Inhibitors
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bruton′s Tyrosine Kinase Inhibitor III | sc-311301 | 1 mg | $390.00 | |||
Bruton's Tyrosine Kinase Inhibitor III is a potent modulator of Btk activity, engaging in specific hydrogen bonding and hydrophobic interactions that enhance its binding affinity. The compound demonstrates unique allosteric effects, altering the conformation of the kinase domain and impacting its catalytic efficiency. Its reaction kinetics reveal a biphasic profile, with an initial fast binding phase followed by a slower stabilization, which influences the overall signaling cascade in cellular environments. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
Ibrutinib covalently binds to BTK's active site, inhibiting its kinase activity and downstream signaling in B-cell malignancies and autoimmune diseases. | ||||||
Terreic Acid | 121-40-4 | sc-200655 sc-200655A | 1 mg 5 mg | $106.00 $421.00 | ||
May function as an inhibitor of Btk, a protein involved in cellular signaling. It likely interferes with Btk's activity, impacting its role in signaling pathways. | ||||||
LFM-A13 | 62004-35-7 | sc-203623 sc-203623A | 10 mg 50 mg | $119.00 $670.00 | ||
LFM-A13 is a selective inhibitor of Bruton's Tyrosine Kinase (Btk) that exhibits remarkable specificity through its unique interaction with the ATP-binding site. The compound's structure facilitates strong van der Waals forces and electrostatic interactions, leading to a stable complex formation. Its kinetic profile showcases a rapid association rate, followed by a gradual dissociation, which fine-tunes the modulation of downstream signaling pathways, enhancing its regulatory potential in cellular processes. | ||||||
Acalabrutinib | 1420477-60-6 | sc-507392 | 250 mg | $255.00 | ||
Acalabrutinib binds covalently to BTK, inhibiting its kinase activity and modulating B-cell signaling pathways in various disorders. | ||||||
(S)-Ibrutinib | 936563-97-2 | sc-491262 sc-491262A | 5 mg 20 mg | $460.00 $1285.00 | ||
(S)-Ibrutinib is a potent inhibitor of Bruton's Tyrosine Kinase (Btk), characterized by its unique stereochemistry that enhances binding affinity. The compound engages in specific hydrogen bonding and hydrophobic interactions within the active site, promoting a conformational change that stabilizes the enzyme-inhibitor complex. Its kinetic behavior reveals a fast on-rate and a prolonged off-rate, allowing for sustained modulation of Btk activity and influencing various cellular signaling cascades. | ||||||
Zanubrutinib | 1691249-45-2 | sc-507434 | 5 mg | $360.00 | ||
Zanubrutinib is a selective BTK inhibitor that covalently binds to the kinase, suppressing B-cell receptor signaling in certain lymphomas. | ||||||
Ibrutinib-d5 | 1553977-17-5 | sc-495736A sc-495736 sc-495736B | 500 µg 1 mg 5 mg | $156.00 $300.00 $1250.00 | 1 | |
Ibrutinib-d5 is a deuterated derivative of Ibrutinib, notable for its selective inhibition of Bruton's tyrosine kinase (Btk). This compound exhibits unique isotopic labeling, which can enhance the understanding of metabolic pathways and molecular interactions in cellular signaling. Its distinct kinetic profile allows for precise tracking in biochemical assays, providing insights into Btk-mediated processes. The incorporation of deuterium may also influence the stability and reactivity of the compound in various experimental conditions. | ||||||
Tirabrutinib | 1351636-18-4 | sc-507435 | 10 mg | $135.00 | ||
ONO/GS-4059 is a selective BTK inhibitor that might modulate B-cell receptor signaling and immune responses. | ||||||
Spebrutinib | 1202757-89-8 | sc-507524 | 100 mg | $375.00 | ||
Spebrutinib is a reversible BTK inhibitor that could affect B-cell receptor signaling and immune cell activation. | ||||||